EUROFINS SCIENT Retained Earnings (Accumulated Deficit) 2018-2024 | ERFSF
EUROFINS SCIENT retained earnings (accumulated deficit) from 2018 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
- EUROFINS SCIENT retained earnings (accumulated deficit) for the quarter ending June 30, 2024 were $2.465B, a 64.64% increase year-over-year.
- EUROFINS SCIENT retained earnings (accumulated deficit) for 2023 were $2.591B, a 5.4% increase from 2022.
- EUROFINS SCIENT retained earnings (accumulated deficit) for 2022 were $2.458B, a 5.76% increase from 2021.
- EUROFINS SCIENT retained earnings (accumulated deficit) for 2021 were $2.324B, a 55.25% increase from 2020.
| EUROFINS SCIENT Annual Retained Earnings (Accumulated Deficit) (Millions of US $) |
|
|---|---|
| 2023 | $2,591 |
| 2022 | $2,458 |
| 2021 | $2,324 |
| 2020 | $1,497 |
| 2019 | $805 |
| 2018 | $779 |
| 2017 | $591 |
| 2016 | $0 |
| 2015 | $0 |
| EUROFINS SCIENT Quarterly Retained Earnings (Accumulated Deficit) (Millions of US $) |
|
|---|---|
| 2023-06-30 | $2,465 |
| 2022-12-31 | $2,458 |
| 2021-12-31 | $2,324 |
| 2021-06-30 | $1,900 |
| 2020-12-31 | $1,497 |
| 2020-06-30 | $904 |
| 2019-12-31 | $805 |
| 2019-06-30 | $672 |
| 2018-12-31 | $779 |
| 2018-06-30 | $664 |
| 2017-12-31 | $591 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $12.351B | $7.522B |
| Eurofins Scientific SE provides testing services. The company provides food and feed testing, bioanalytical, biopharma, pharma discovery, pharma early development, pharma central laboratory, biopharma product testing, genomic, agroscience, consumer product testing, forensic, environment testing and REACH services. It operates primarily in Benelux, France, Germany, North America, Nordic countries, the United Kingdom, Ireland and internationally. Eurofins Scientific SE is headquartered in Luxembourg. | |||